{"news_desk": "Business", "print_page": null, "subsection_name": "DealBook", "section_name": "Business Day", "byline": {"original": "By ROBERT CYRAN", "person": [{"firstname": "Robert", "rank": 1, "lastname": "CYRAN", "organization": "", "role": "reported"}]}, "abstract": null, "type_of_material": "News", "word_count": "396", "keywords": [{"rank": "1", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "name": "subject"}, {"rank": "2", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "name": "subject"}, {"rank": "3", "value": "Pfizer Inc", "is_major": "N", "name": "organizations"}, {"rank": "4", "value": "Read, Ian C", "is_major": "N", "name": "persons"}], "lead_paragraph": "Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up.", "pub_date": "2016-09-27T04:00:00+0000", "document_type": "article", "source": "The New York Times", "snippet": "Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbWide.jpg"}, {"height": 400, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/09/27/business/dealbook/pfizer-remains-whole-but-the-option-to-split-could-return.html", "slideshow_credits": null, "blog": [], "_id": "57e95e8895d0e021d7988700", "headline": {"main": "Pfizer Remains Whole, but the Option to Split Could Return", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}}